GENELUX Corp — Director's Dealing 2023

Aug 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GENELUX Corp (GNLX)
CIK: 0001231457
Period of Report: 2023-08-30

Reporting Person: Yu Yong (VP, Clinical Trial Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-30	Common Stock	S	19800	$24.70	Disposed	135935	Direct

Footnotes

F1: The weighted average sale price for the transaction reported was $24.70, and the range of prices were between $24.70 and $24.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.